Compare Ally Financial Inc (ALLY) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ally Financial Inc vs DexCom, Inc. — how do they compare? Ally Financial Inc trades at $45.64 (market cap $13.97B), while DexCom, Inc. trades at $74.97 (market cap $28.93B). The key difference: DexCom, Inc. is far larger — about 2.1× Ally Financial Inc's market cap, and Ally Financial Inc pays a 2.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| ALLY | DXCM | |
|---|---|---|
Market Cap | $13.97B | $28.93B |
Sector | Financials | Health |
52-Week High | $47.25 | $89.53 |
52-Week Low | $35.96 | $54.84 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
